CCR5 antagonists:  a therapeutic option in HIV-1 perinatally infected children experiencing virologic failure?
Two-thirds of HAART-failing children could benefit from CCR5 antagonists-based strategies, even in case of triple-class virologic failure. Such therapy should be discussed more appropriately at early stages of infection, when CCR5-tropic strains are most frequently isolated. However, before considering such strategies, further studies are needed to evaluate the efficacy and the tolerability of CCR5 antagonists in this pediatric population.
Chronic stress may reveal or exacerbate symptoms of masticatory dysfunction.